Drugs & OTC

Anatara Lifesciences Ltd (ASX:ANR) CEO Steven Lydeamore Interview

🕔2/21/2020 8:39:05 PM

Anatara Lifesciences Ltd (ASX:ANR) CEO Steven Lydeamore was recently interviewed by Stockhead, for its "90 Seconds With" interview series. Steve provided an overview of the Company's key milestones for the next 12 months.

Read Full Article

Cann Global Limited (ASX:CGB) Share Placement

🕔2/17/2020 9:58:39 AM

Cann Global Ltd (ASX:CGB) is pleased to advise that the Company has agreed to place 34 million new fully paid ordinary shares (New Shares) to institutional and sophisticated investors led by New York-based Sea Otter Global.

Read Full Article

Cann Global Limited (ASX:CGB) Quarterly Activities and Cashflow Report

🕔2/3/2020 8:18:29 AM

Cann Global Limited (ASX:CGB) was pleased to announce a distribution agreement with Costco Australia for our premium quality certified organic hemp seed oil capsules in September.

Read Full Article

Cann Global Limited (ASX:CGB) New Costco and Epco Purchase Orders

🕔1/23/2020 8:24:07 AM

The Board of Cann Global Limited (ASX:CGB) is pleased to provide an update on its recent exclusive distributorship supply contract deal signed with EPCO Foods Co. Ltd in Ho Chi Minh City, Vietnam and its supply of T12 products to COSTCO Australia.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Preclinical Program Summary

🕔1/22/2020 11:23:32 AM

Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide a summary of the preclinical studies conducted to date for its Gastrointestinal ReProgramming (GaRP) dietary supplement as it targets commencement of a human clinical trial in 2Q 2020.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Quarterly Cashflow

🕔1/15/2020 8:40:10 AM

Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 31st December 2019. The Company's cash plus term deposits at the end of the quarter stood at $4.30m

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Finalises Draft Protocol for IBS Clinical Trial

🕔12/20/2019 8:21:26 AM

Anatara Lifesciences (ASX:ANR) is pleased to provide an update on the protocol for its clinical trial in irritable bowel syndrome (IBS) for its GaRP dietary supplement.

Read Full Article